| Atiprimod |
NCT00430014 |
Terminated |
Phase 1 |
Study of Atiprimod Treatment for Patients With Advanced Cancer |
Advanced Cancer |
https://ClinicalTrials.gov/show/NCT00430014 |
| Atiprimod |
NCT00214838 |
Unknown status |
Phase 1|Phase 2 |
An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer |
Advanced Cancer |
https://ClinicalTrials.gov/show/NCT00214838 |
| Atiprimod |
NCT00388063 |
Completed |
Phase 2 |
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma |
Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT00388063 |
| Atiprimod |
NCT00663429 |
Completed |
Phase 2 |
Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma |
Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT00663429 |
| Atiprimod |
NCT00086216 |
Completed |
Phase 1|Phase 2 |
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma |
Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00086216 |
